Literature DB >> 18814817

Signet-ring cell carcinoma arising from the urinary bladder.

Imre Romics1, Eszter Székely, Attila Szendroi.   

Abstract

INTRODUCTION: Signet-ring cell carcinoma of the urinary bladder can be primary - arising from the bladder wall or urachus remnants - or metastatic from tumors originating in the stomach, colon, or breast. Saphir first described primary signet-ring cell cancer of the urinary bladder in 1955. Less than 100 cases have been reported in the literature since then. CASE REPORT: We report a case of a 45-year-old woman who was admitted with gross hematuria. Cystoscopy revealed a necrotic tumor on the left bladder wall. A transurethral biopsy showed signet-ring cell carcinoma. The bladder tumor was diagnosed as the primary one. Radical cystectomy was performed with ureterosigmoidostomy (Mainz pouch II). Histological examination showed a primary signet-ring cell carcinoma of the bladder (pT3bN0M0). Following surgery, the patient received adjuvant chemotherapy with cisplatin and fluorouracil.
CONCLUSIONS: Primary signet-ring cell carcinoma of the urinary bladder is an extremely rare tumor, accounting for approximately 0.24% of all bladder malignances. Patients with this type of cancer generally have a poor prognosis. However, our patient is free of disease 5 years after radical cystectomy.

Entities:  

Mesh:

Year:  2008        PMID: 18814817

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  9 in total

1.  Immunohistochemical and ultrastructural characterization of the signet-ring cell carcinoma component in a case of urothelial carcinoma of the urinary bladder.

Authors:  Yuji Ohtsuki; Tetsuya Fukumoto; Yuhei Okada; Yuki Teratani; Yoshihiro Hayashi; Gang-Hong Lee; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

2.  Metastatic signet ring cell adenocarcinoma of the bladder: responsive to treatment?

Authors:  Jessica Singh; Viktor Zherebitskiy; David Grynspan; Piotr Marek Czaykowski
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  A Series of Primary Signet Ring Cell Carcinoma of the Urinary Bladder.

Authors:  B Nerli Rajendra; Nitin D Pingale; Shridhar C Ghagane; Ameya T Wagh; Prakah R Malur
Journal:  Indian J Surg Oncol       Date:  2017-05-04

4.  Primary urachal mucinous adenocarcinoma of the urinary bladder.

Authors:  Iqbal Singh; Ravi Prasad
Journal:  J Clin Diagn Res       Date:  2013-05-01

5.  Primary Signet-Ring Cell Carcinoma of the Urinary Bladder Successfully Managed with Radical Cystectomy in a Young Patient.

Authors:  Farzad Allameh; Morteza Fallah Karkan; Yalda Nilipour; Azadeh Rakhshan
Journal:  Case Rep Urol       Date:  2017-06-05

6.  Primary Mucinous Adenocarcinoma of the Urinary Bladder with Signet-Ring Cells: Description of an Uncommon Case and Critical Points in Its Management.

Authors:  Fabrizio Di Maida; Giuliano Amorim Aita; Daniele Amorim Aita
Journal:  Case Rep Urol       Date:  2016-12-18

7.  Clinicopathological Characteristics and Prognostic Factors of Primary Bladder Signet Ring Cell Carcinoma.

Authors:  Liang Liu; Qiang Wang; Haibo Yuan
Journal:  J Healthc Eng       Date:  2022-09-05       Impact factor: 3.822

8.  Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy.

Authors:  Takashi Hamakawa; Yoshiyuki Kojima; Taku Naiki; Yasue Kubota; Takahiro Yasui; Keiichi Tozawa; Yutaro Hayashi; Kenjiro Kohri
Journal:  Case Rep Urol       Date:  2013-05-08

9.  Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.

Authors:  Moon Jin Kim; Young Sam Kim; Sung Yong Oh; Suee Lee; Young-Jin Choi; Young Mi Seol; Min Jae Park; Ki Hyang Kim; Lee Chun Park; Jung Hun Kang; In-Gyu Hwang; Soon Il Lee; Seung Taek Lim; Hyo Song Kim; Ho Yeong Lim; Sun Young Rha; Hyo-Jin Kim
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.